To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Preclinical evaluation of purported acute stroke therapies plays a significant role in the drug development process. Animal stroke models and their use in evaluating treatment effects of potential acute stroke therapies are prone to many difficulties. Recently, it has been proposed that diffusion-perfusion MRI might help to bridge the gap between preclinical evaluation and advanced clinical trials. Several reports have appeared concerning the use of PWI and DWI to assess thrombolytic therapy in animal stroke models. Combining Perfusion MRI (PWI) and Diffusion MRI (DWI) in temporary occlusion models evaluating neuroprotective drugs may also be useful. The use of diffusion-perfusion MRI both in preclinical testing and in clinical development of acute stroke therapies will likely continue to expand, especially once the MRI modalities provide support for the approval of a new acute stroke therapy. Their utility will also increase as we move into the multitherapy era of acute stroke therapy.
Email your librarian or administrator to recommend adding this to your organisation's collection.